Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ad5-yCD-mutTKSR39rep-hIL12 |
Synonyms | |
Therapy Description |
Ad5-yCD/mutTKSR39rep-hIL12 is an oncolytic adenovirus engineered to express the cytokine interleukin-12 (IL-12) gene and two suicide fusion genes, which induces both tumor cell lysis and anti-tumor immune response (PMID: 26767191). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ad5-yCD-mutTKSR39rep-hIL12 | Ad5-yCD/mutTKSR39rep-hIL12 is an oncolytic adenovirus engineered to express the cytokine interleukin-12 (IL-12) gene and two suicide fusion genes, which induces both tumor cell lysis and anti-tumor immune response (PMID: 26767191). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03281382 | Phase I | Ad5-yCD-mutTKSR39rep-hIL12 | Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer | Completed | USA | 0 |